MA38155A1 - Utilisation du pidotimod pour traiter le psoriasis - Google Patents

Utilisation du pidotimod pour traiter le psoriasis

Info

Publication number
MA38155A1
MA38155A1 MA38155A MA38155A MA38155A1 MA 38155 A1 MA38155 A1 MA 38155A1 MA 38155 A MA38155 A MA 38155A MA 38155 A MA38155 A MA 38155A MA 38155 A1 MA38155 A1 MA 38155A1
Authority
MA
Morocco
Prior art keywords
pidotimod
treat psoriasis
psoriasis
acceptable salt
physiologically acceptable
Prior art date
Application number
MA38155A
Other languages
English (en)
Other versions
MA38155B1 (fr
Inventor
Federico Mailland
Maurizio Caserini
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA38155A1 publication Critical patent/MA38155A1/fr
Publication of MA38155B1 publication Critical patent/MA38155B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention porte sur l'utilisation du pidotimod ou de son sel physiologiquement acceptable pour traiter le psoriasis. Dans l'invention, le pidotimod ou son sel physiologiquement acceptable peut être administré par voie systémique ou topique pour traiter le psoriasis.
MA38155A 2012-12-19 2012-12-19 Utilisation du pidotimod pour traiter le psoriasis MA38155B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076088 WO2014094840A1 (fr) 2012-12-19 2012-12-19 Utilisation du pidotimod pour traiter le psoriasis

Publications (2)

Publication Number Publication Date
MA38155A1 true MA38155A1 (fr) 2016-02-29
MA38155B1 MA38155B1 (fr) 2016-09-30

Family

ID=47520054

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38155A MA38155B1 (fr) 2012-12-19 2012-12-19 Utilisation du pidotimod pour traiter le psoriasis

Country Status (31)

Country Link
US (1) US20150328191A1 (fr)
EP (1) EP2934521B1 (fr)
JP (1) JP6051315B2 (fr)
KR (1) KR20150095773A (fr)
CN (1) CN104869994B (fr)
AR (1) AR094027A1 (fr)
AU (1) AU2012396942A1 (fr)
BR (1) BR112015011391A2 (fr)
CA (1) CA2887878A1 (fr)
CY (1) CY1118645T1 (fr)
DK (1) DK2934521T3 (fr)
EA (1) EA201591185A1 (fr)
ES (1) ES2617235T3 (fr)
HK (1) HK1210937A1 (fr)
HR (1) HRP20161666T1 (fr)
HU (1) HUE031846T2 (fr)
IL (1) IL239429A0 (fr)
LT (1) LT2934521T (fr)
MA (1) MA38155B1 (fr)
ME (1) ME02560B (fr)
MX (1) MX2015008104A (fr)
PH (1) PH12015501210A1 (fr)
PL (1) PL2934521T3 (fr)
PT (1) PT2934521T (fr)
RS (1) RS55436B1 (fr)
SG (1) SG11201503270UA (fr)
SI (1) SI2934521T1 (fr)
SM (1) SMT201700072B (fr)
TN (1) TN2015000142A1 (fr)
WO (1) WO2014094840A1 (fr)
ZA (1) ZA201502573B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036009A1 (fr) * 2013-09-10 2015-03-19 Polichem S.A. Pidotimod à utiliser dans le traitement de maladies associées à une inflammation
CA3019164A1 (fr) * 2016-03-29 2017-10-05 Janssen Biotech, Inc. Methode de traitement du psoriasis par l'augmentation de l'espacement des doses d'anticorps anti-il-12/23
CN105943505A (zh) * 2016-05-26 2016-09-21 杭州百诚医药科技股份有限公司 一种匹多莫德药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) * 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2003018011A1 (fr) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substitue)-5-(substitue sulfonyl ou sulfanyl)thiazolidine-2,4-diones utiles pour l'inhibition de la farnesyl-proteine transferase

Also Published As

Publication number Publication date
KR20150095773A (ko) 2015-08-21
CY1118645T1 (el) 2017-07-12
ES2617235T3 (es) 2017-06-15
HUE031846T2 (hu) 2017-08-28
EP2934521A1 (fr) 2015-10-28
EA201591185A1 (ru) 2016-02-29
CN104869994A (zh) 2015-08-26
SG11201503270UA (en) 2015-07-30
PH12015501210A1 (en) 2015-08-17
JP6051315B2 (ja) 2016-12-27
CN104869994B (zh) 2016-10-12
EP2934521B1 (fr) 2016-11-30
CA2887878A1 (fr) 2014-06-26
HK1210937A1 (en) 2016-05-13
WO2014094840A1 (fr) 2014-06-26
DK2934521T3 (en) 2017-02-06
ME02560B (fr) 2017-02-20
AU2012396942A2 (en) 2015-07-30
LT2934521T (lt) 2016-12-27
ZA201502573B (en) 2016-11-30
RS55436B1 (sr) 2017-04-28
US20150328191A1 (en) 2015-11-19
PT2934521T (pt) 2017-03-03
PL2934521T3 (pl) 2017-06-30
SMT201700072B (it) 2017-03-08
SI2934521T1 (sl) 2017-03-31
AU2012396942A1 (en) 2015-07-02
MA38155B1 (fr) 2016-09-30
JP2016503043A (ja) 2016-02-01
MX2015008104A (es) 2015-11-06
AR094027A1 (es) 2015-07-08
TN2015000142A1 (en) 2016-10-03
HRP20161666T1 (hr) 2017-01-27
IL239429A0 (en) 2015-07-30
BR112015011391A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
EA201491391A1 (ru) Терапевтически активные соединения и способы их применения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
IN2015DN01156A (fr)
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
CL2012001293A1 (es) Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
CA3010788A1 (fr) Procedes d'administration de vasopresseurs
MA38155B1 (fr) Utilisation du pidotimod pour traiter le psoriasis
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем
AU2014365665A1 (en) Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
MA38156B1 (fr) Utilisation du pidotimod pour traiter la dermatite atopique
MX2017007856A (es) Composicion para el cuidado bucal.
FR2992219B1 (fr) Composition pour le traitement de l'hypocalcemie chez les ruminants
EA201200720A1 (ru) Способ лечения системного слабо выраженного воспаления
FR2990859B1 (fr) Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
FR2976492B1 (fr) Electrode combinee pour le traitement de l'hyperhidrose axillaire
MA38455A1 (fr) Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
FR2976493B1 (fr) Electrode combinee pour le traitement de l'hyperhidrose